Kidney Care Partners
Health care
Based in DC
🤖
AI Overview
With $1.6M in lobbying spend across 26 quarterly filings, Kidney Care Partners is a significant lobbying presence.
$1.6M
Total Lobbying Spend
26
Quarterly Filings
1
Lobbying Firms Used
1
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $180K |
| 2019 | $180K |
| 2020 | $240K |
| 2021 | $120K |
| 2022 | $240K |
| 2023 | $240K |
| 2024 | $180K |
| 2025 | $195K |
Lobbying Firms
LESTER HEALTH LAW PLLC
What They Lobby For
- Affordable Care Act Implementation; Marketplace Stabilization Rules; Charitable Premium Assistance
- ESRD Prospective Payment System CY 2018 and CY 2019 and Quality Incentive Program PY 2019-21 and PY 2022; ESRD Dialysis Facility Compare/Five Star; implementation of ESRD PPS for CY 2017; HR 2644 Chronic Kidney Disease Improvement in Research and Treatment Act of 2017; S. 1890 Chronic Kidney Disease Improvement in Research and Treatment Act of 2017
- ESRD Prospective Payment System CY 2019 and Quality Incentive Program PY 2019-22; ESRD Dialysis Facility Compare/Five Star; implementation of ESRD PPS for CY 2018; HR 2644 Chronic Kidney Disease Improvement in Research and Treatment Act of 2017; S. 1890 Chronic Kidney Disease Improvement in Research and Treatment Act of 2017
- Implementation of ESRD Prospective Payment System (PPS) CY 2020 and Quality Incentive Program (QIP) PY 2020-23 Proposed Rule; ESRD Five Star Program; Proposed ESRD PPS and QIP rules
- Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules;
- Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
- Implementation of ESRD Prospective Payment System (PPS) CY 2020 and Quality Incentive Program (QIP) PY 2020-23 Proposed Rule; ESRD Five Star Program; Proposed ESRD PPS and QIP rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; ESRD Treatment Choices Model proposed rule
- Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; OPO proposed rule; HRSA organ compensation proposed rule
- Implementation of ESRD Prospective Payment System (PPS) CY 2020 and Quality Incentive Program (QIP) PY 2020-23 Proposed Rule; ESRD Five Star Program; Proposed ESRD PPS and QIP rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; ESRD Treatment Choices Model proposed rule; ESRD Voluntary physician models
- Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; OPO proposed rule; HRSA organ compensation proposed rule, CARES Act
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.